scholarly journals Vibration Response Imaging in Idiopathic Pulmonary Fibrosis: A Pilot Study

2013 ◽  
Vol 59 (7) ◽  
pp. 1071-1077
Author(s):  
Q.-x. Liu ◽  
W.-j. Guan ◽  
Y.-q. Xie ◽  
J.-y. An ◽  
M. Jiang ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Vibration Response ◽  
Vibration Response Imaging

8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study

Lung ◽  
2019 ◽  
Vol 197 (1) ◽  
pp. 81-88
Author(s):  
Baruch Vainshelboim ◽  
Mordechai Reuven Kramer ◽  
Jonathan Myers ◽  
Avraham Unterman ◽  
Shimon Izhakian ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Prospective Pilot Study

Usefulness of Body Composition CT Analysis in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study

2021 ◽  
Author(s):  
Carole Jalaber ◽  
Jeanne Lemerre-Poincloux ◽  
Stéphane Jouneau ◽  
Chloé Rousseau ◽  
Bertrand Dolou ◽  
...  
Keyword(s):  
Body Composition ◽  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Ct Analysis

scholarly journals DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study

2021 ◽  
Vol 15 ◽  
pp. 175346662110425
Author(s):  
Martina Doubkova ◽  
Eva Kriegova ◽  
Simona Littnerova ◽  
Petra Schneiderova ◽  
Martina Sterclova ◽  
...  
Keyword(s):  
Pilot Study ◽  
Lung Function ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Vital Capacity ◽  
Cross Validation ◽  
Healthy Individuals ◽  
Lung Capacity ◽  
Diffuse Lung ◽  
Antifibrotic Drugs

Background: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF. Methods: MUC5B rs35705950 and DSP rs2076295 were assessed in IPF patients ( n = 210, 139 men/71 women) from the Czech EMPIRE registry and age- or sex-matched healthy individuals ( n = 205, 125 men/80 women). Genetic data were collated with overall survival (OS), acute exacerbation episodes, worsening lung function and antifibrotic treatment. Results: We confirmed overexpression of the MUC5B rs35705950*T allele (55.2% versus 20.9%, p < 0.001) and the DSP rs2076295*G allele (80.4% versus 68.3%, p < 0.001) in IPF compared with controls. On antifibrotic drugs, lower mortability was observed in IPF patients with DSP G* allele ( p = 0.016) and MUC5B T* allele ( p = 0.079). Carriers of the DSP rs2076295*G allele benefitted from nintedanib treatment compared with TT genotype by a longer OS [hazard ratio (HR) = 7.99; 95% confidence interval (CI) = 1.56–40.90; p = 0.013] and a slower decline in lung function (HR = 8.51; 95% CI = 1.68–43.14; p = 0.010). Patients with a TT genotype (rs2076295) benefitted from treatment with pirfenidone by prolonged OS ( p = 0.040; HR = 0.35; 95% CI = 0.13–0.95) compared with nintedanib treatment. Both associations were confirmed by cross-validation analysis. After stratifying by MUC5B rs35705950*T allele carriage, no difference in treatment outcome was observed for nintedanib or pirfenidone ( p = 0.784). In the multivariate model, smoking, age, forced vital capacity (FVC) and DLCO (diffuse lung capacity) at the IPF diagnosis were associated with survival. Conclusion: Our real-world study showed that IPF patients with MUC5B T* allele or DSP G* allele profit from antifibrotic treatment by lower mortability. Moreover, carriers of the DSP rs2076295*G allele benefit from treatment with nintedanib, and TT genotype from treatment with pirfenidone. MUC5B rs35705950 did not impact the outcome of treatment with either nintedanib or pirfenidone. Our single-registry pilot study should be confirmed with an independent patient cohort.

scholarly journals Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis—a pilot study

2017 ◽  
Vol 12 (1) ◽  
pp. 016003 ◽  
Author(s):  
Barbara Rindlisbacher ◽  
Carina Strebel ◽  
Sabina Guler ◽  
Attila Kollár ◽  
Thomas Geiser ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Potential Biomarker ◽  
Breath Condensate

scholarly journals Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study

2018 ◽  
Vol 10 (12) ◽  
pp. 6660-6669 ◽  
Author(s):  
Dragana Jovanovic ◽  
Marina Roksandic Milenkovic ◽  
Jelena Kotur Stevuljevic ◽  
Jelena Markovic ◽  
Vesna Ceriman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Plasma Levels
Sign in / Sign up

Export Citation Format

Share Document